Jade Biosciences
JBIO
72 hedge funds and large institutions have $57.8M invested in Jade Biosciences in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 19 closing their positions.
356% more call options, than puts
Call options by funds: $301K | Put options by funds: $66K
28% more capital invested
Capital invested by funds: $45.1M → $57.8M (+$12.7M)
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
0.04% more ownership
Funds ownership: 2.69% → 2.74% (+0.04%)
10% less funds holding
Funds holding: 80 → 72 (-8)
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$894K |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$737K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$662K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$529K |
| 5 |
Morgan Stanley
New York
|
+$520K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$1.34M |
| 2 |
Millennium Management
New York
|
-$821K |
| 3 |
SG Americas Securities
New York
|
-$310K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$275K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$247K |
JBIO Hedge Fund Activity: Q3 2024 in Review
72 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q3 2024, worth a combined $57.8M — up 28% from $45.1M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of JBIO and 11 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 23 added.
The largest buyer was Eversept Partners, opening a new position worth an estimated $894K. The largest seller was Artal Group, exiting entirely with an estimated $1.34M sold.
- 72 institutional investors held Jade Biosciences (JBIO) as of Q3 2024, down from 80 in Q2 2024.
- Funds reported $57.8M of Jade Biosciences stock for Q3 2024, up 28% quarter-over-quarter.
- 11 funds opened new Jade Biosciences positions in Q3 2024 and 19 closed out, a net change of -8 holders.
- The largest Jade Biosciences buyer in Q3 2024 was Eversept Partners, an estimated $894K added.
- The largest Jade Biosciences seller in Q3 2024 was Artal Group, an estimated $1.34M sold.
Based on aggregated 13F filings for Q3 2024.